Introduction
============

Colorectal cancer (CRC) contributes greatly to cancer mortality and morbidity worldwide.[@b1-cmar-10-2663] Diverse morphologic features and behavior have been reported for this disease. Many studies have suggested a difference in terms of genetics, biology, and demography between right and left-sided CRC (RCC and LCC, respectively). RCC and LCC are viewed as two different lesions and their biological and demographic characteristics differ.[@b2-cmar-10-2663]

Ethnicity is an important contributing factor among the variables affecting the incidence rates of CRC. There are racial disparities in the CRC incidence among African-Americans and Hispanics.[@b3-cmar-10-2663] African-Americans form a unique cohort of patients for whom CRC data, trends, and characteristics remain unclear.[@b4-cmar-10-2663] African-Americans are more likely to be diagnosed with advanced stage CRC and to have poorer survival rates after diagnosis compared to Whites.[@b5-cmar-10-2663] On the basis of the results of clinical trials in the USA with a high proportion of non-Hispanic Whites, various adjuvant chemotherapy regimens for colon cancer have been introduced in East Asian countries.[@b6-cmar-10-2663] Hispanics have a lower overall incidence rate of CRC as compared to non-Hispanic Whites.[@b4-cmar-10-2663] The survival rates of African-American patients diagnosed with colon cancer is considerably lower than that of White patients.[@b7-cmar-10-2663] To better understand the results of numerous studies and clinical trials performed worldwide, it would be useful to determine potential prognostic differences due to race/ethnicity after surgery for colon cancer.

Many factors contribute to CRC incidence, including ethnicity, sex, diet/environment, and socioeconomic status. Many of these variables have been explored, but many unanswered questions remain. The CRC incidence rate increases with age.[@b8-cmar-10-2663],[@b9-cmar-10-2663] However, information on the RCC/LCC ratio disparities among different ethnicities is rare. Understanding the age-related changes in the clinicopathologic features of CRC is very important for the implementation of age-related preventive/therapeutic measures. The study may also give a clue that the patients' inclusion in clinical trials should consider not only tumor location but also ethnicity, given the different reactions of patients of different ethnicities to targeted agents since there is a difference in race in the population that benefited from the bevacizumab trial.[@b10-cmar-10-2663]--[@b12-cmar-10-2663]

Although several reports have documented the characteristics of CRC in the elderly, to the best of our knowledge, ethnicity-specific, age-related changes in CRC characteristics, especially those focusing on detailed cancer localization and ethnicity, have not been fully investigated. The present study aimed to clarify the ethnicity-specific, age-related changes in the clinicopathologic features of CRC.

Materials and methods
=====================

Samples
-------

The study was conducted based on the Surveillance, Epidemiology, and End Results (SEER) programs and did not require review board approval. The SEER registries (Connecticut, Iowa, Hawaii, New Mexico, Utah, and the metropolitan areas of Atlanta, Detroit, San Francisco-Oakland, and Seattle Puget Sound) represent \~9% of the US population.[@b13-cmar-10-2663] We collected the information of individuals with pathologically diagnosed disease from 2004 to June 2012. All patients had a first diagnosis of invasive, non-distant, metastatic colon cancer according to the American Joint Committee on Cancer sixth edition criteria. All patients had pathologically confirmed adenocarcinoma or mucinous adenocarcinoma, and tumors were graded based on definition, that is, as well, moderate, poor, or undifferentiated. Colon cancer was evaluated as right sided (transverse colon, hepatic flexure, ascending colon, cecum), left sided (sigmoid colon, descending colon, splenic flexure), or rectosigmoid colon (rectum, rectosigmoid junction). The total number of lymph nodes (TNLN) evaluated was recorded and they were considered categorical variables if the node number was =12. The SEER nine dataset categorized ethnicity as White, African-American, Native American/Alaska Native, Asian/Pacific Islander, and unknown.[@b14-cmar-10-2663] As the sample for Native American/Alaska Native patients was small,[@b14-cmar-10-2663]--[@b16-cmar-10-2663] the data for this group were not analyzed.

Patients were observed from 6 months after the first diagnosis of colon cancer until the last follow-up, death, or the end of the study, whichever occurred first.

Statistical analysis
--------------------

Univariate logistic analysis was used to assess the correlation of age and clinicopathologic variables, tumor depth (Tis--T2, T3--T4), histologic type (well/moderate/poor differentiation), regional lymph node metastasis, distant metastasis, ethnicity, and tumor size. The correlation between patient age and clinicopathologic characteristics was evaluated by parametric and nonparametric methods. The parametric method was carried out for variables of sex, tumor depth, distant metastasis, chemotherapy, and pathologic type using the unpaired Student's *t*-test. The nonparametric method was used for the ordered variables such as regional lymph node metastasis, radiotherapy, pathology grade, the number of lymph nodes retrieved, tumor size, and the tumor location using the Spearman's rank correlation coefficient. Significant variables affecting patient age were assessed by multivariate analysis using a logistic regression model. Kaplan--Meier survival analysis was used to compare the difference in survival based on tumor location. All analyses were performed with SPSS version 13.0, and a two-sided value of *P*\<0.05 was considered statistically significant.

Ethics approval
---------------

This article does not contain any studies with human participants or animals performed by any of the authors.

Results
=======

Patients' characteristics
-------------------------

Overall, there were 270,390 patients in our cohort. [Table 1](#t1-cmar-10-2663){ref-type="table"} lists the general patient features. The patient age ranged 11--85 years (mean age, 68±13.1 years); 30,905 patients (11.4%) were African-Americans, 218,495 (80.8%) were Whites, and the remaining 20,990 (7.8%) were Asian/Pacific Islanders. [Figure 1](#f1-cmar-10-2663){ref-type="fig"} shows the ethnicity variation according to age. The sample size variation in this study could be accepted according to the study by Siegel et al.[@b7-cmar-10-2663] Additionally, we compared all the variants among the ethnic groups (Table S1).

Univariate analysis and multivariate analysis
---------------------------------------------

[Table 1](#t1-cmar-10-2663){ref-type="table"} shows the results of the univariate analysis of the association between the clinicopathologic variables and age, according to ethnicity, in patients with CRC. The African-American patients were older in cases with RCC (*P*\<0.001), of female sex (*P*\<0.001), with advanced N stage (*P*\<0.001), without M1 (*P*\<0.001), without treatment (*P*\<0.001), and with poor differentiation (*P*\<0.001), TNLN \<12 (*P*\<0.001), and smaller tumor size (*P*\<0.001). No correlation between patient age and the other clinicopathologic variables was observed. In Asian/Pacific Islander and White patients, the age-associated variables were similar to those of the African-American patients.

Independent variables correlating with age ≥70 years were identified using multivariate logistic regression analysis ([Table 2](#t2-cmar-10-2663){ref-type="table"}). In the African-American patients, female sex (odds ratio \[OR\]=1.28, *P*\<0.001), late N stage (N1 vs No, OR=0.424); M0 stage (OR=0.804, *P*\<0.001), without chemotherapy (OR=0.304, *P*\<0.001), pathology grade (moderate vs well, OR=1.120, *P*=0.010; poor vs well, OR=1.266, *P*\<0.001; undifferentiated vs well, OR=1.352, *P*=0.004), TNLN \<12 (OR=0.712, *P*\<0.001), and RCC (LCC vs RCC, OR=0.672, *P*\<0.001; rectal cancer vs RCC, OR=0.696, *P*\<0.001) were independent variables correlated with higher age. Similarly, in White and Asian/Pacific Islander patients, the presence of advanced T stage and smaller tumor size were additional independent variables.

RCC, female sex, TNLN \<12, no to moderate differentiation, late N stage, and M0 stage without chemotherapy were the common independent variables with age ≥70 years in the African-American, White, and Asian/Pacific Islander patients.

Variation of RCC ratio with age
-------------------------------

The RCC/rectum or RCC/LCC ratio was relatively low in patients aged \<70 years, but was increased in patients aged ≥70 years ([Table 3](#t3-cmar-10-2663){ref-type="table"}). Tumor location was an independent factor associated with patient age in all three ethnic groups. [Figure 2](#f2-cmar-10-2663){ref-type="fig"} shows the distribution of RCC tumors according to the age group. The shift of preferential tumor location to the proximal colon with increased age was more prominent in White patients than in African-American and Asian/Pacific Islander patients. In White patients, only 27.2% and 23.4% of patients aged \<60 and 60--69 years, respectively, had RCC, but this increased to 49.4% in patients aged ≥70 years. In Asian/Pacific Islander patients, only 34.3% and 25% of patients aged \<60 and 60--69 years, respectively, had RCC, but this increased to 40.7% in patients aged ≥70 years. The correlation between tumor location and age was stronger in White and Asian/Pacific Islander patients than in African-American patients (*P*\<0.001). In African-American patients, 28.9% and 24% of patients aged \<60 and 60--69 years, respectively, had RCC, and it increased to 35.5% in the patients aged ≥70 years.

The RCC shift with age was present in the subgroup (tumor stage, differentiation, tumor size, TNLN, sex) analysis ([Figures S1](#SD1-cmar-10-2663){ref-type="supplementary-material"}[](#SD2-cmar-10-2663){ref-type="supplementary-material"}--[3](#SD3-cmar-10-2663){ref-type="supplementary-material"} for African-Americans, Asian/Pacific patients and Whites, respectively). We noted a big shift in RCC in White patients aged ≥70 years, and the significance remained in the subgroup analysis. The RCC ratio was increased at least two times in the patients aged ≥70 years compared with the patients aged \<70 years.

Survival comparison
-------------------

In the African-American patients, there was no survival difference between RCC, LCC, and rectal cancer in each age group ([Figure 3A](#f3-cmar-10-2663){ref-type="fig"}). In the Asian/Pacific Islander patients, RCC survival was relatively poorer only in the 50--59 years age group ([Figure 3B](#f3-cmar-10-2663){ref-type="fig"}). However, in White patients, RCC survival was poor in the age groups 40--49, 50--59, 60--69, and ≥70 years ([Figure 3C](#f3-cmar-10-2663){ref-type="fig"}). RCC survival difference inferiority was most apparent in the Whites.

Discussion
==========

In our study, RCC was an independent variable correlated with age ≥70 years in the African-American, White, and Asian/Pacific Islander patients with CRC. The significance remained in the subgroup analysis, especially in White patients. Additionally, the RCC survival disadvantage as compared to LCC/rectal cancer was present only in the White patients.

Early-stage tumors and low-grade phenotype are more frequent in older patients.[@b17-cmar-10-2663]--[@b19-cmar-10-2663] The present study reveals a higher percentage of poorly differentiated, lymph node--positive, and non-M1 tumors in patients aged ≥70 years, which is consistent with previous studies. Although we are uncertain why these discrepancies exist, both environmental and genetic factors might play a role in it.

The detection of colon cancer is rare in people aged \<50 years, which is similar to previous reports.[@b17-cmar-10-2663],[@b18-cmar-10-2663] Here, we observed that the RCC ratio increased gradually with age, which agrees with previous population-based reports.[@b2-cmar-10-2663] Additionally, trend analysis of incidence data between 2004 and 2014 revealed that RCC incidence increased by 23.5%, and the trend was most apparent in White patients, where RCC increased by two to three times in patients aged ≥70 years. That is, right-sided lesions predominate in older age groups, whereas there are more LCC/rectal cancer cases in younger and middle-aged patients, especially among Whites.

Racial disparities in CRC incidence have been established in the literature.[@b4-cmar-10-2663] Socioeconomic status, comorbidity rates, and cancer biology could contribute to this.[@b20-cmar-10-2663],[@b21-cmar-10-2663] The reason for the ethnicity difference in terms of tumor location in younger patients is unclear. However, it may have clinical implications and may direct research in the future. Our results support the premise that screening endoscopy has a differential preventive effect on RCC and LCC. Our findings are also supported by Baxter et al,[@b22-cmar-10-2663] who reported that colonoscopy reduces mortality in LCC significantly (by 70%), but apparently does not have a significant effect on mortality in RCC. External factors, such as overlooked lesions of the proximal colon and/or inadequate coverage of the whole colon during colonoscopy, may be pertinent. Fuccio et al reported faster growth of right-sided adenomas as compared to left-sided adenomas, implying a smaller chance for detecting proximal colonic polyps by screening.[@b23-cmar-10-2663] However, Meza et al reported the opposite: slower growth of proximal colonic polyps than that of distal colonic and rectal polyps, which is sex specific and consistent with the delayed onset of RCC as opposed to LCC. Our study argues that the biological characteristic differences are predominant in older patients, especially among White patients. For screening CRC in the general population, our findings indicate the importance of screening schedules that distinguish the variances between ethnicities[@b23-cmar-10-2663],[@b24-cmar-10-2663] and the possible benefits of differential targeting of screening strategies for right- and left-sided lesions at different ages. Considering these findings, future trials involving colonoscopy should power recruitment appropriately to enable a priori stratified analyses for right- and left-sided neoplastic endpoints. Such modeling improvements will certainly yield more reliable risk predictions, better informing policymakers on the economic strategies for screening and interventions for preventing CRC more effectively at a population level.

Wong et al reported that among White patients who received bevacizumab, patients with RCC had the most obvious progression-free survival benefit.[@b10-cmar-10-2663] However, Brenner et al revealed the apparent survival advantage in LCC when chemotherapy was combined with bevacizumab.[@b25-cmar-10-2663] Moreover, in metastatic CRC in Chinese and wide *KRAS*-wide patients, the combination of cetuximab and chemotherapy enhanced the objective response rate, progression-free survival, and overall survival in LCC cases without survival benefit in RCC.[@b11-cmar-10-2663],[@b12-cmar-10-2663] This indicates that patient inclusion in clinical trials should consider not only tumor location, but also ethnicity, given the different reactions of patients of different ethnicities to targeted agents.

Two distinct mechanistic pathways have been suggested in the carcinogenesis of sporadic CRC: chromosomal instability (CIN) and microsatellite instability (MSI).[@b26-cmar-10-2663] CIN is more common in cancers arising from the distal colon and rectum than in those from the proximal colon.[@b26-cmar-10-2663] Most sporadic high MSI CRC tends to occur in the proximal (right-side) colon in the elderly.[@b26-cmar-10-2663],[@b27-cmar-10-2663] In contrast, sporadic CRC in elderly patients, which have MSI, is usually generated by hypermethylation of a DNA mismatch repair gene, such as *MLH1* and the subsequent loss of the MLH1 protein.[@b28-cmar-10-2663] Poorly differentiated adenocarcinoma is often observed in high MSI CRC. As this feature of CRC in older White patients resembles that of CRC with MSI in the present study, MSI may be an important carcinogenic pathway of CRC in elderly White patients, and this will be an important matter of future investigation. Therefore, we may speculate that the increased prevalence of concomitant adenomas with increased age in the elderly may be associated with colorectal carcinogenesis through the CIN pathway.

In the African-American patients, there was no survival difference between RCC and LCC among all age groups. Similarly, in Asian/Pacific Islander patients, RCC survival was poorest only in the 50--59 years age group. However, in White patients, RCC survival was poorest in the age groups 40--49, 50--59, 60--69, and ≥70 years; the tumor location survival difference was more apparent only in White patients. The potential reason remains unknown, although income difference and socioeconomic status are the possible reasons. White patients present with later-stage cancer and are more likely to undergo cancer-directed surgery than patients of other ethnicities, and LCC itself could reflect a survival advantage.[@b29-cmar-10-2663]

There are some limitations to our study. First, its retrospective nature renders the data potentially vulnerable to bias. We were unable to properly assess personal and family history of CRC, and we did not evaluate familial adenomatous polyposis. However, one of our exclusion criteria was personal or family history of colorectal adenoma or carcinoma, although previous reports did not stipulate this exclusion criterion.[@b30-cmar-10-2663],[@b31-cmar-10-2663] Hence, our cohort may sufficiently represent the average risk population with reasonably generalizable prevalence estimates. The other limitation is that socioeconomic status is not available in the SEER database, but socioeconomic differences exist in different races and they may influence the survival and diagnosis of CRC.

Lastly, there were differences between the younger and older patient populations, with adverse factors being more common in patients aged \<70 years. Moreover, the frequency of RCC differed according to age and ethnicity, wherein the frequency of RCC was relatively high in all ethnicities studied, especially in White patients.

Conclusion
==========

The study found more adverse prognosis in younger patients compared to older patients. Tumor location frequency differed based on age; the most pronounced differences were found in White patients. There was relatively high RCC incidence in patients from all ethnicities studied, especially in White patients. The RCC survival inferiority was present only in White patients.
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###### 

Distribution of tumor location according to age group in the African-American subgroups.

**Notes:** (**A**) Stage; (**B**) pathology (differentiation); (**C**) TNLN; (**D**) tumor size (\<40, 40--70, and ≥70 mm); (**E**) sex. The shift for the proximal predominance of CRC increased with age.

**Abbreviations:** CRC, colorectal cancer; TNLN, total number of lymph nodes.

###### 

Distribution of tumor location according to age group in the Asian/Pacific Islander subgroups.

**Notes:** (**A**) Stage; (**B**) pathology (differentiation); (**C**) TNLN; (**D**) tumor size (\<40, 40--70, and ≥70 mm); (**E**) sex. The shift for the proximal predominance of CRC increased with age.

**Abbreviations:** CRC, colorectal cancer; TNLN, total number of lymph nodes.

###### 

Distribution rate of tumor location according to age group in the White subgroups.

**Notes:** (**A**) Stage; (**B**) pathology (differentiation); (**C**) TNLN; (**D**) tumor size (\<40, 40--70, and ≥70 mm); (**E**) sex. The shift for the proximal predominance of CRC increased with age.

**Abbreviations:** CRC, colorectal cancer; TNLN, total number of lymph nodes.
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![African-American, White, and Asian/Pacific Islander patients in each age group.\
**Note:** The White ethnicity ratio increased with patient age, and this tendency was more prominent in the population aged ≥70 years.](cmar-10-2663Fig1){#f1-cmar-10-2663}

![Distribution of tumor location according to age group in the whole cohort and in the African-American, White, and Asian/Pacific Islander patients, respectively.\
**Notes:** The shift for the proximal predominance of CRC with patient age was more remarkable in White patients than in African-American and Asian/Pacific Islander patients.\
**Abbreviation:** CRC, colorectal cancer.](cmar-10-2663Fig2){#f2-cmar-10-2663}

![(**A--C**) The survival difference of RCC, LCC, and rectosigmoid colon cancer in the African-American, White, and Asian/Pacific Islander patients.\
**Abbreviations:** LCC, left-sided colon cancer; RCC, right-sided colon cancer.](cmar-10-2663Fig3){#f3-cmar-10-2663}

###### 

Univariate analysis of the association between clinicopathologic variables and age in patients of different races

  Patient characteristics     African-American   White   Asian/Pacific Islander                                                
  --------------------------- ------------------ ------- ------------------------ --------- ------- --------- -------- ------- ---------
  **Sex**                                                \<0.001                                    \<0.001                    \<0.001
                                                         \<0.001                                                               
  Male                        15,078             63±12                            112,370   68±13             10,706   65±13   
  Female                      15,827             65±13                            106,125   71±13             10,284   67±14   
  **T stage**                                            0.989                                      \<0.001                    0.974
  Tis, T0, T1, T2             8,842              65±12                            66,115    69±12             6.068    66±12   
  T3--T4 (4, 5)               22,063             64±13                            152,380   69±13             14,922   66±14   
  **N stage**                                            \<0.001                                    \<0.001                    \<0.001
  N0                          16,873             65±12                            127,545   71±13             11,254   67±13   
  N1                          8,648              64±13                            54,227    68±13             5,805    65±13   
  N2                          5,384              62±12                            36,723    66±14             3,931    63±14   
  **Distant metastasis**                                 \<0.001                                    \<0.001                    \<0.001
  M0                          25,865             65±13                            190,352   70±13             18,208   66±13   
  M1                          5,040              62±13                            28,143    65±14             2,782    63±14   
  **Chemotherapy**                                       \<0.001                                    \<0.001                    \<0.001
  No                          19,025             67±12                            139,239   74±12             12,261   70±13   
  Yes                         11,880             59±12                            79,256    62±13             8,729    60±13   
  **Radiotherapy**                                       \<0.001                                    \<0.001                    \<0.001
  No                          64                 67±13                            623       74±13             66       70±14   
  Yes                         2,907              59±12                            26,112    61±12             2,959    59±13   
  Unknown                     27,934             65±13                            191,760   71±13             17,965   67±13   
  **Pathology grade**                                    \<0.001                                    \<0.001                    \<0.001
  Well differentiated         2,735              65±12                            18,756    69±13             1,475    65±13   
  Moderately differentiated   21,740             64±13                            146,085   69±13             14,931   66±13   
  Poorly differentiated       4,364              64±13                            38,025    71±14             3,392    65±15   
  Undifferentiated            539                63±14                            5,434     71±14             309      65±15   
  Unknown                     1,527              63±12                            10,195    66±13             882      63±13   
  **Pathologic type**                                    0.010                                      \<0.001                    \<0.001
  Adenocarcinoma              30, 522            64±12                            215,169   69±12             20,774   66±13   
  Mucinous carcinoma          383                63±13                            3,326     68±13             216      67±14   
  **Number of lymph nodes**                              \<0.001                                    \<0.001                    \<0.001
  \<12                        8,618              66±12                            72,386    70±12             7,235    68±13   
  ≥12                         22,287             64±13                            146,109   69±13             13,755   65±14   
  **Tumor site**                                         \<0.001                                    \<0.001                    \<0.001
  RCC                         16,413             66±12                            107,706   73±12             7,572    70±13   
  LCC                         9,129              63±12                            60,004    67±13             7,635    65±13   
  Rectum                      5,363              61±12                            50,785    64±13             5,783    62±13   
  **Tumor sizes (mm)**                                   \<0.001                                    \<0.001                    \<0.001
  ≤40                         12,958             65±12                            97,720    70±13             10.009   67±13   
  40--70                      11,227             64±13                            73,224    70±14             6,941    66±14   
  ≥70                         6,720              63±13                            47,551    67±14             4,040    64±14   

**Abbreviations:** LCC, left-sided colon cancer; RCC, right-sided colon cancer.

###### 

Multivariate logistic regression analysis for identifying independent variables correlating with patient age ≥70 years

  Patient characteristic                 African-American       White     Asian/Pacific Islander                                    
  -------------------------------------- ---------------------- --------- ------------------------ --------- ---------------------- ---------
  **Sex**                                                                                                                           
  Female vs male                         1.275 (1.215--1.339)   \<0.001   1.332 (1.308--1.357)     \<0.001   1.165 (1.099--1.235)   \<0.001
  **T stage**                                                                                                                       
  T3--T4 vs Tis, T0--T2                                                   1.514 (1.480--1.549)     \<0.001   1.375 (1.278--1.480)   \<0.001
  **N stage**                                                   \<0.001                            \<0.001                          \<0.001
  N0                                     1.000                            1.000                              1.000                  
  N1                                     1.424 (1.337--1.517)   \<0.001   1.259 (1.228--1.291)     \<0.001   1.364 (1.261--1.475)   \<0.001
  N2                                     1.264 (1.168--1.368)   \<0.001   1.105 (1.072--1.139)     \<0.001   1.165 (1.061--1.280)   0.001
  **Distant metastasis**                                                                                                            
  Yes vs no                              0.804 (0.746--0.867)   \<0.001   0.769 (0.746--0.793      \<0.001   0.783 (0.711--0.862)   \<0.001
  **Chemotherapy**                                                                                                                  
  Yes vs no                              0.304 (0.286--0.323)   \<0.001   0.250 (0.244--0.256)     \<0.001   0.284 (0.265--0.305)   \<0.001
  **Radiotherapy**                                                                                 \<0.001                          
  No                                                                      1.000                                                     
  Yes                                                                     0.672 (0.565--0.799)     \<0.001                          
  Unknown                                                                 0.725 (0.611--0.860)     \<0.001                          
  **Pathology grade**                                                                              \<0.001                          \<0.001
  Well differentiated                    1.000                            1.000                              1.000                  
  Moderately differentiated              1.120 (1.027--1.221)   0.010     1.139 (1.102--1.177)     \<0.001   1.309 (1.165--1.470)   \<0.001
  Poorly differentiated                  1.266 (1.139--1.407)   \<0.001   1.386 (1.333--1.441)     \<0.001   1.308 (1.142--1.499)   \<0.001
  Undifferentiated                       1.352 (1.104--1.655)   0.004     1.426 (1.335--1.524)     \<0.001   1.430 (1.094--1.869)   0.009
  Unknown                                0.851 (0.740--0.979)   0.024     0.902 (0.856--0.951)     \<0.001   1.037 (0.862--0.249)   0.699
  **Pathologic type**                                                                                                               
  Mucinous carcinoma vs adenocarcinoma   0.699 (0.556--0.879)   0.002     0.695 (0.645--0.750)     \<0.001                          
  **Number of lymph nodes**                                                                                                         \<0.001
  ≥12 vs \<12                            0.712 (0.674--0.752)   \<0.001   0.711 (0.697--0.725)     \<0.001   0.656 (0.616--0.699)   \<0.001
  **Tumor size (mm)**                                           \<0.001                            \<0.001                          \<0.001
  ≤40                                    1.000                            1.000                              1.000                  
  40--70                                 1.076 (1.018--1.138)   0.010     1.002 (0.980--1.024)     0.868     0.963 (0.899--1.033)   0.292
  ≥70                                    0.845 (0.791--0.902)   \<0.001   0.819 (0.799--0.839)     \<0.001   0.775 (0.714--0.840)   \<0.001
  **Tumor site**                                                \<0.001                            \<0.001                          \<0.001
  RCC                                    1.000                            1.000                              1.000                  
  LCC                                    0.672 (0.635--0.711)   \<0.001   0.507 (0.496--0.518)     \<0.001   0.536 (0.500--0.574)   \<0.001
  Rectum                                 0.696 (0.647--0.748)   \<0.001   0.502 (0.489--0.516)     \<0.001   0.537 (0.497--0.581)   \<0.001

**Abbreviations:** LCC, left-sided colon cancer; OR, odds ratio; RCC, right-sided colon cancer.

###### 

Location of new CRC according to age group

  Age (years)   Total     Right     Left     Rectum   Right/left                                          Right/rectum
  ------------- --------- --------- -------- -------- --------------------------------------------------- ---------------------------------------------------
  \<40          8,087     2,688     2,680    2,719    1.00[\*](#tfn3-cmar-10-2663){ref-type="table-fn"}   0.99[\*](#tfn3-cmar-10-2663){ref-type="table-fn"}
  40--49        19,787    6,313     6,624    6,850    0.95[\*](#tfn3-cmar-10-2663){ref-type="table-fn"}   0.92[\*](#tfn3-cmar-10-2663){ref-type="table-fn"}
  50--59        50,231    18,151    16,706   15,374   1.09[\*](#tfn3-cmar-10-2663){ref-type="table-fn"}   1.18[\*](#tfn3-cmar-10-2663){ref-type="table-fn"}
  60--69        64,942    29,346    19,419   16,177   1.51[\*](#tfn3-cmar-10-2663){ref-type="table-fn"}   1.81[\*](#tfn3-cmar-10-2663){ref-type="table-fn"}
  ≥70           127,343   75,193    31,339   20,811   2.40[\*](#tfn3-cmar-10-2663){ref-type="table-fn"}   3.61[\*](#tfn3-cmar-10-2663){ref-type="table-fn"}
  Total         270,390   131,691   76,768   61,931   1.72[\*](#tfn3-cmar-10-2663){ref-type="table-fn"}   2.13[\*](#tfn3-cmar-10-2663){ref-type="table-fn"}

**Notes:**

The proportion of right-sided lesions increased with age (*P*=0.01, by chi-squared trend test). Left column reflects left-sided colon cancer; right column reflects right-sided colon cancer. The Right/left column reflects the means the ratio of right-sided colon cancer to left-sided and the Right/rectum column reflects the ratio of right-sided colon cancer to rectum cancer.

**Abbreviation:** CRC, colorectal cancer.

[^1]: These authors contributed equally to this work
